Medical/Pharmaceuticals
BPK9 International Hospital Achieves GHA Accreditation for Medical Travel Services
PALM BEACH GARDENS, Fla., Dec. 14, 2022 /PRNewswire/ -- Global Healthcare
Accreditation (GHA) is pleased to announce that BPK9 International Hospital in
Bangkok, Thailand (https://www.bangpakokhospital.com/en/
2022-12-14 19:00
3832
Superior Results Of The Comparative Study Of The Company's Recombinant Two-Component COVID-19 Vaccine ReCOV As Compared To International Mainstream mRNA Vaccine
TAIZHOU, China, Dec. 14, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that positive results were achieved for its sequential booster vaccination Phase II study of the recombinant twocomponent COVID-19 ...
2022-12-14 15:17
5783
CGTN: 'New Approaches': Hospitals gear up to prioritize COVID-19 patients
BEIJING, Dec. 14, 2022 /PRNewswire/ -- To echo China's new guidelines for COVID-19 prevention and control, local governments and hospitals across the country have been optimizing medical services and the allocation of medical resources to face a likely surge in patients and take better care of th...
2022-12-14 12:36
4033
Sirnaomics Executive Director Dr. Xiaochang Dai to Deliver Keynote Speech at BIOHK2022
GERMANTOWN, Md. and HONG KONG, Dec. 14, 2022 /PRNewswire/ -- Sirnaomics Ltd. ( the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in the discovery and development of advanced therapeutics centered around the messenger RNA ("mRNA"), announced today that its Ex...
2022-12-14 01:41
5096
Treadwell Therapeutics Announces A Presentation at the 2022 ASH Annual Meeting Featuring a Clinical Trial Update on CFI-400945, an oral PLK4 inhibitor
NEW YORK, Dec. 13, 2022 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel, small molecule therapeutics for highly aggressive cancers, today announced a presentation for the Company's CFI-400945 program, a first in class inhibitor of Polo-like Kinase ...
2022-12-13 22:30
5799
VeriSIM Life Earns Frost & Sullivan Competitive Strategy Leadership Award for Best Practices in AI-enabled Preclinical Development Industry
VeriSIM Life eliminates waste and inaccuracy, accelerates preclinical development, and lowers costs and risks when converting drug candidates to clinical trials, and brings life-saving drugs to market faster. SAN ANTONIO, Dec. 13, 2022 /PRNewswire/ -- Frost & Sullivan recently assessed the artif...
2022-12-13 21:00
2732
HistoSonics Announces $100 Million in Financings and New Appointment to its Board of Directors
Financings Planned to Support Rapid Expansion of Histotripsy Platform as
Company Welcomes Silk Road Medical CEO,Erica Rogers, to its Board of Directors
MINNEAPOLIS, Dec. 13, 2022 /PRNewswire/ -- HistoSonics, Inc. (
www.histosonics.com
2022-12-13 20:00
2771
CUVET Successfully Developed the First Stem Cell Transplantation Technology to Treat Pet Diabetes
BANGKOK, Dec. 13, 2022 /PRNewswire/ -- For the first time in Thailand, a research team from Chula's Faculty of Veterinary Science (CUVET), led by Assistant Professor Dr. Chenpop Sawangmek in collaboration with Bio ink Co., Ltd., a Chula spinoff company, has successfully developed a method to cultu...
2022-12-13 17:35
4748
RemeGen's RC118 for Injection Targeting Claudin 18.2 in Patients with Gastric and Pancreatic Cancers Granted Two Orphan Drug Designations by U.S. FDA
YANTAI, China, Dec. 13, 2022 /PRNewswire/ -- RemeGen Co., Ltd.
2022-12-13 12:30
3429
Luye Pharma and DCH Auriga Establish an Exclusive Distribution Partnership and Jointly Launch the "We Care About Mental Health" Initiative
* Luye Pharma has granted DCH Auriga Singapore exclusive distribution and marketing rights for Seroquel® and Seroquel XR® in Singapore. * The two companies pledge to make joint effort to raise awareness of mental health issues as part of the "We Care About Mental Health" initiative. SINGAPORE ...
2022-12-13 12:14
7349
Youth at Risk of Being Left Behind in Asia Pacific Tuberculosis Response, Regional Forum Spotlights
Johnson & Johnson, together with the Global Fund and Asian Venture Philanthropy Network, convene 2nd annual Asia Pacific Tuberculosis Forum to advance progress toward ending tuberculosis in the region Youth are at risk of being missed from diagnosis if not engaged and empowered in fight against ...
2022-12-13 10:07
4113
CSL Announces Next CEO & Managing Director
Dr Paul McKenzie appointed Chief Executive Officer and Managing Director of CSL from6 March 2023 MELBOURNE, Australia, Dec. 13, 2022 /PRNewswire/ -- The Board of Directors of CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that it has appointed DrPaul McKenzie as Chief Executive Officer (CEO)...
2022-12-13 07:23
4907
Patients and Doctors Agree on Treatment Goals Only Half the Time, According to JNCCN Study on People with Neuroendocrine Tumors
Researchers from City of Hope find only 30% of people with neuroendocrine tumors consider living longer to be their single top priority; 70% said addressing and overcoming pain, fatigue, or lack-of-function was more important than just prolonging life. JNCCN announces five new Associate Editors ...
2022-12-13 06:19
2214
Ascletis Announces Positive Phase I Clinical Results of Oral RdRp Inhibitor ASC10 for COVID-19
--The exposure of active drug ASC10-A after twice daily dosing 800 mg double prodrug ASC10 in Chinese subjects was 94% of that after twice daily dosing 800 mg single prodrug molnupiravir in Japanese subjects --Based on Ascletis' Phase I results of ASC10 and molnupiravir's clinical efficacy data ...
2022-12-12 23:29
5551
Frost & Sullivan Recognizes VitalConnect with the 2022 New Product Innovation Award for Its Leading-edge Wearable Patient Monitoring Device
VitalConnect delivers a cost-effective, 24/7 remote patient monitoring platform that outperforms existing patient monitoring devices on the market. SAN ANTONIO, Texas, Dec. 12, 2022 /PRNewswire/ -- Based on its recent analysis of the wearable biosensor industry,Frost & Sullivan recognizes VitalC...
2022-12-12 22:00
2986
JW Therapeutics Presents Latest Clinical Data on Carteyva® in Follicular Lymphoma and Mantle Cell Lymphoma at the 64th ASH Annual Meeting
SHANGHAI, Dec. 12, 2022 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, presented the latest clinical data on Carteyva® (relmacabtagene autoleucel injection) in...
2022-12-12 18:00
6123
Alphamab Oncology Presented Clinical Data of KN026 Combined with Docetaxel in first-line treatment of HER2-positive recurrent/metastatic breast cancer at SABCS 2022
* As of August 18, 2022，the confirmed ORR for 55 evaluable subjects was 76.4% and DoR was 24.0 months. The disease control rate was 100% in 55 evaluable subjects. * The median follow-up for PFS was 16.6 months. The median PFS was calculated as 25.4 months and yet to become mature. * The med...
2022-12-12 15:51
2749
Alphamab Oncology Presented Clinical Data of KN026 Combined with Docetaxel as neoadjuvant treatment for HER2-positive early or locally advanced breast cancer at SABCS 2022
* As of Sep 10, 2022, 20 patients completed the surgery and pathological evaluation, tpCR rate were 50%, bpCR rate were 55.0%, and ORR were 100%. * In terms of safety, the incidence Grade ≥3 TEAE were 53.3% (16/30)。The incidence of SAE was 6.7% (2/30) with only one case related to KN026. SUZHO...
2022-12-12 15:00
2965
China further optimizes COVID-19 response with new measures
BEIJING, Dec. 12, 2022 /PRNewswire/ -- A report from People's Daily: Local authorities across China have soon made specific policies to implement the 10 new prevention and control measures recently rolled out by the country on further optimizing the COVID-19 response, so as to contain the epidemi...
2022-12-12 11:38
2668
Alphamab Oncology Presented Final Analysis of KN046 Combined with Nab-paclitaxel in the Treatment of mTNBC at SABCS 2022
* As of August 21, 2022, the ORR from 25 efficacy evaluable TNBC patients was 44.0%, the DCR was 96.0%, and the CBR was 52.0%. * The median follow-up time was 27.93 months. The median PFS was 7.33 months. Among the PD-L1 ≥1% pts, the median PFS was 8.61 months. * The median OS was not mature...
2022-12-12 10:33
3290
Week's Top Stories
Most Reposted
SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 282 media titles]
2026-10-07 11:50DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 279 media titles]
2026-10-06 05:28Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 274 media titles]
2026-10-09 13:21The Coffee Bean & Tea Leaf® Turns 63 and Sets a New Direction for Its Next Chapter of Growth
[Picked up by 263 media titles]
2026-10-05 13:24
Most Read
RoboParty Unveils RP1, a High-Performance Full-Stack Open-Source Humanoid Robot at IROS
2026-10-04 00:56
10600
Nuix Neo Generative AI Framework
2026-10-08 08:02
9072
Silicon Quantum Computing Named to Fast Company's 2026 Next Big Things in Tech List
2026-10-06 19:38
8074
